Skip to main content
SpringerLink
Log in

“There is no dose–response relationship in psychopharmacotherapy” vs “pharmacotherapy in psychiatry is based on ligand–receptor interaction”: a unifying hypothesis and the need for plasma concentration based clinical trials

  • Commentary
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  • Anonymous (1985) Tricyclic antidepressants—blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry. Am J Psychiatry 142:155–162

    Google Scholar 

  • Adli M, Baethge C, Heinz A, Langlitz N, Bauer M (2005) Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255:387–400

    Article  PubMed  Google Scholar 

  • Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML, Eckermann G, Gerlach M, Kuss HJ, Laux G, MuellerOerlinghausen B, Riederer P, Zernig G (2004) Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guidelines. Ther Drug Monit 26:1–4

    Article  Google Scholar 

  • Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF (1989) Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 25:71–79

    PubMed  CAS  Google Scholar 

  • Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165:988–995

    Article  PubMed  Google Scholar 

  • Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Moller HJ (1998) The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neuroscience 248:96–103

    Article  CAS  Google Scholar 

  • Kenakin TP (2006) A pharmacology primer. Theory, application, and methods. Elsevier, Amsterdam

  • Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826–835

    Article  PubMed  Google Scholar 

  • Ostad E, Tadic A, Wagner S, Dragicevic A, Möller MJ, Boland J, Rao ML, Fric M, Laux G, Hiemke C (2011) Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychpharmacol 31: in press

  • Rasmussen BB, Brosen K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22:143–154

    Article  PubMed  CAS  Google Scholar 

  • Suzuki Y, Fukui N, Sawamura K, Sugai T, Watanabe J, Ono S, Inoue Y, Ozdemir V, Someya T (2008) Concentration–response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression. J Clin Psychopharmacol: 325–8

  • Tanum L, Strand LP, Refsum H (2010) Serum concentrations of citalopram–dose-dependent variation in R- and S-enantiomer ratios. Pharmacopsychiatry 43:190–193

    Article  PubMed  CAS  Google Scholar 

  • Tasker TC, Kaye CM, Zussman BD, Link CG (1989) Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatrica Scand Suppl 350:152–155

    Article  CAS  Google Scholar 

  • Uhr M, Grauer MT, Holsboer F (2003) Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54:840–846

    Article  PubMed  CAS  Google Scholar 

  • Ulrich S, Wurthmann C, Brosz M, Meyer FP (1998) The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinetics 34:227–263

    Article  CAS  Google Scholar 

  • Zernig G, Ahmed SH, Cardinal RN, Morgan D, Acquas E, Foltin RW, Vezina P, Negus SS, Crespo JA, Stockl P, Grubinger P, Madlung E, Haring C, Kurz M, Saria A (2007) Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests. Pharmacology 80:65–119

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by the Verein für Experimentelle Psychiatrie, Psychotherapie und Pharmakologie (VEPPP).

Conflicts of interest

Vincent Eggart reports no conflict of interest. Christoph Hiemke has received speaker’s or consultancy fees from the following pharmaceutical companies: Bristol-Myers Squibb, Pfizer, Lilly and Servier. He reports no conflict of interest with this publication. Gerald Zernig has received speaker’s or consultancy fees or unrestricted educational grants from AlcaSynn, AstraZeneca, Bio-Rad, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Mundipharma, Novartis, Pfizer, and Wyeth. He reports no conflict of interest.

Author information

Authors and Affiliations

  1. Experimental Psychiatry Unit, Center of Psychiatry and Psychotherapy, Department of General Psychiatry and Social Psychiatry, Medical University Innsbruck, Innrain 66 a, room 35-G1-010, A-6020, Innsbruck, Austria

    Vincent Eggart & Gerald Zernig

  2. Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany

    Christoph Hiemke

Authors
  1. Vincent Eggart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Hiemke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerald Zernig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald Zernig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eggart, V., Hiemke, C. & Zernig, G. “There is no dose–response relationship in psychopharmacotherapy” vs “pharmacotherapy in psychiatry is based on ligand–receptor interaction”: a unifying hypothesis and the need for plasma concentration based clinical trials. Psychopharmacology 217, 297–300 (2011). https://doi.org/10.1007/s00213-011-2319-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-011-2319-z

Keywords

Search

Navigation